Native profiles of α1A‐adrenoceptor phenotypes in rabbit prostate

[1]  J A Peters,et al.  Guide to Receptors and Channels (GRAC), 3rd edition , 2008, British journal of pharmacology.

[2]  T. Tanaka,et al.  Identification of the α1L‐adrenoceptor in rat cerebral cortex and possible relationship between α1L‐ and α1A‐adrenoceptors , 2008, British journal of pharmacology.

[3]  H. Akino,et al.  Assessment of muscarinic receptor subtypes in human and rat lower urinary tract by tissue segment binding assay. , 2008, Journal of Pharmacological Sciences.

[4]  R A John Challiss,et al.  "Phenotypic" pharmacology: the influence of cellular environment on G protein-coupled receptor antagonist and inverse agonist pharmacology. , 2007, Biochemical pharmacology.

[5]  H. Akino,et al.  Identification of alpha-1L and alpha-1A adrenoceptors in human prostate by tissue segment binding. , 2007, The Journal of urology.

[6]  H. Akino,et al.  Identification of α-1L and α-1A Adrenoceptors in Human Prostate by Tissue Segment Binding , 2007 .

[7]  S. Morishima,et al.  Pharmacological evaluation of plasma membrane beta-adrenoceptors in rat hearts using the tissue segment binding method. , 2006, Life sciences.

[8]  A. Anisuzzaman,et al.  Quantifying receptor properties: the tissue segment binding method - a powerful tool for the pharmacome analysis of native receptors. , 2005, Journal of pharmacological sciences.

[9]  Takashi Tanaka,et al.  Identification of α-1L Adrenoceptor in Rabbit Ear Artery , 2004, Journal of Pharmacology and Experimental Therapeutics.

[10]  G. Milligan,et al.  High-affinity interactions between human α1A-adrenoceptor C-terminal splice variants produce homo- and heterodimers but do not generate the α1L-adrenoceptor , 2004 .

[11]  Li Zhang,et al.  Alpha‐1 adrenoceptors: evaluation of receptor subtype‐binding kinetics in intact arterial tissues and comparison with membrane binding , 2004, British journal of pharmacology.

[12]  G. Milligan,et al.  High-affinity interactions between human alpha1A-adrenoceptor C-terminal splice variants produce homo- and heterodimers but do not generate the alpha1L-adrenoceptor. , 2004, Molecular pharmacology.

[13]  Takashi Tanaka,et al.  Identification of alpha-1L adrenoceptor in rabbit ear artery. , 2004, The Journal of pharmacology and experimental therapeutics.

[14]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[15]  K. Andersson.  Alpha-adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoceptor antagonists. , 2002, World journal of urology.

[16]  J. Faber,et al.  Expression of α-Adrenoceptor Subtypes by Smooth Muscle Cells and Adventitial Fibroblasts in Rat Aorta and in Cell Culture , 2001 .

[17]  C. Chapple.  Alpha adrenoceptor antagonists in the year 2000: is there anything new? , 2001, Current opinion in urology.

[18]  J. Faber,et al.  Expression of alpha-adrenoceptor subtypes by smooth muscle cells and adventitial fibroblasts in rat aorta and in cell culture. , 2001, The Journal of pharmacology and experimental therapeutics.

[19]  G. Michelotti,et al.  α1-Adrenergic receptor regulation: basic science and clinical implications , 2000 .

[20]  J. McGrath,et al.  An alpha(1A)/alpha(1L)-adrenoceptor mediates contraction of canine subcutaneous resistance arteries. , 2000, The Journal of pharmacology and experimental therapeutics.

[21]  T. Taniguchi,et al.  Cloning of rabbit alpha(1b)-adrenoceptor and pharmacological comparison of alpha(1a)-, alpha(1b)- and alpha(1d)-adrenoceptors in rabbit. , 2000, European journal of pharmacology.

[22]  G. Michelotti,et al.  Alpha 1-adrenergic receptor regulation: basic science and clinical implications. , 2000, Pharmacology & therapeutics.

[23]  H. Zhong,et al.  α1-Adrenoceptor subtypes , 1999 .

[24]  M. Takeda,et al.  α1- and α2-Adrenoceptors in BPH , 1999, European Urology.

[25]  T. Taniguchi,et al.  Pharmacological analysis of the novel, selective α1‐adrenoceptor antagonist, KMD‐3213, and its suitability as a tritiated radioligand , 1999, British journal of pharmacology.

[26]  J. Gever,et al.  Human cloned α1A-adrenoceptor isoforms display α1L-adrenoceptor pharmacology in functional studies , 1999 .

[27]  J. Gever,et al.  Human cloned alpha1A-adrenoceptor isoforms display alpha1L-adrenoceptor pharmacology in functional studies. , 1999, European journal of pharmacology.

[28]  J. McKiernan,et al.  Alpha-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia. , 1999, Drugs.

[29]  M. Takeda,et al.  alpha1- and alpha2-adrenoceptors in BPH. , 1999, European Urology.

[30]  H. Zhong,et al.  Alpha1-adrenoceptor subtypes. , 1999, European journal of pharmacology.

[31]  J. Gever,et al.  Pharmacological pleiotropism of the human recombinant α1A‐adrenoceptor: implications for α1‐adrenoceptor classification , 1997 .

[32]  J. Hieble,et al.  Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): role of the alpha-1L adrenoceptor in tissue selectivity, part II. , 1997, The Journal of pharmacology and experimental therapeutics.

[33]  P. H. van der Graaf,et al.  Analysis of alpha1-adrenoceptors in rabbit lower urinary tract and mesenteric artery. , 1997, European journal of pharmacology.

[34]  J. Gever,et al.  Pharmacological pleiotropism of the human recombinant alpha1A-adrenoceptor: implications for alpha1-adrenoceptor classification. , 1997, British journal of pharmacology.

[35]  T. Stamey,et al.  RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: implications for adrenoceptor classification. , 1996, Molecular pharmacology.

[36]  T. Kenakin,et al.  On the importance of the "antagonist assumption" to how receptors express themselves. , 1995, Biochemical pharmacology.

[37]  R. Lefkowitz,et al.  International Union of Pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update. , 1995, Pharmacological reviews.

[38]  H. Lepor,et al.  Prostatic alpha adrenoceptors. , 1994, Progress in clinical and biological research.

[39]  G. Strada,et al.  Characterization of α1-adrenoceptor subtypes in prostate and prostatic urethra of rat, rabbit, dog and man , 1993 .

[40]  G. Strada,et al.  Characterization of alpha 1-adrenoceptor subtypes in prostate and prostatic urethra of rat, rabbit, dog and man. , 1993, European journal of pharmacology.

[41]  M. Caron,et al.  Molecular biology of α-adrenergic receptors: implications for receptor classification and for structure-function relationships , 1991 .

[42]  M. Caron,et al.  Molecular biology of alpha-adrenergic receptors: implications for receptor classification and for structure-function relationships. , 1991, Biochimica et Biophysica Acta.

[43]  I. Muramatsu,et al.  Pharmacological subclassification of α1‐adrenoceptors in vascular smooth muscle , 1990 .

[44]  I. Muramatsu,et al.  Pharmacological subclassification of alpha 1-adrenoceptors in vascular smooth muscle. , 1990, British journal of pharmacology.

[45]  N. Flavahan,et al.  Alpha-1 and alpha-2 adrenoceptor: response coupling in canine saphenous and femoral veins. , 1986, The Journal of pharmacology and experimental therapeutics.

[46]  N. Flavahan,et al.  α1-Adrenoceptor subclassification in vascular smooth muscle , 1986 .

[47]  Drew Gm.  What do antagonists tell us about alpha-adrenoceptors? , 1985 .

[48]  G. M. Drew.  What do antagonists tell us about alpha-adrenoceptors? , 1985, Clinical science.

[49]  R. Furchgott.  The Classification of Adrenoceptors (Adrenergic Receptors). An Evaluation from the Standpoint of Receptor Theory , 1972 .

[50]  H. Schild,et al.  SOME QUANTITATIVE USES OF DRUG ANTAGONISTS , 1997, British journal of pharmacology and chemotherapy.